SGLT2 Inhibitors For Diabetes
Inhibition of SGLT2 leads to a reduction in blood glucose levels. Therefore, SGLT2 inhibitors have potential use in the treatment of type II diabetes. Several drug candidates have been developed or are currently undergoing clinical trials, including:
- Dapagliflozin, approval rejected by Food and Drug Administration due to safety concerns, but marketed in Europe
- Canagliflozin, approved in the United States
- Ipragliflozin (ASP-1941), in Phase III clinical trials
- Tofogliflozin, in Phase III clinical trials
- Empagliflozin (BI-10773), in Phase III clinical trials
- Sergliflozin etabonate, discontinued after Phase II trials
- Remogliflozin etabonate, in phase IIb trials
Read more about this topic: SLC5A2